Inhibrx Biosciences, Inc.INBXNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank74
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

Latest
10.97%
↑ 125% vs avg
Percentile
P74
Within normal range
Streak
1 qtr
Consecutive growthAccelerating
Average
-43.81%
Historical baseline
PeriodValue
Q4 202510.97%
Q3 2025-12.96%
Q2 202516.60%
Q1 202517.88%
Q4 2024-43.27%
Q3 202447.88%
Q2 20248.72%
Q1 2024-6.48%
Q4 2023-9.46%
Q3 2023-29.19%
Q2 2023-6.63%
Q1 2023-29.48%
Q4 2022-0.16%
Q3 2022-13.12%
Q2 2022-0.69%
Q1 2022-18.22%
Q4 2021-65.32%
Q3 202139.26%
Q2 2021-5.23%
Q1 2021-35.38%
Q4 2020-12.83%
Q3 2020-21.51%
Q2 2020-56.05%
Q1 202039.08%
Q4 2019-727.29%
Q3 201989.75%
Q2 2019-156.00%
Q1 201924.83%
Q4 20180.00%
Q2 2018-517.54%
Q1 201869.76%
Q4 20170.00%